Evidence is mounting that ctDNA is a viable tool to study therapy response dynamics, understand resistance, and design personalized cancer treatments.

MRD is gaining traction as a predictive biomarker for risk assessment, outcome prediction and deciphering the mechanisms of resistance. Here’s why.

Neoantigen-based cancer vaccines represent new, truly personalized therapeutic approaches to treating cancer.